Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ECE1 | P42892 | 1/20 | 0.58 |
| ▸ | CPB1 | P15086 | 1/20 | 0.58 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.58 |
| ▸ | ACE | P12821 | 1/20 | 0.58 |
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | FNTA | P49354 | 1/20 | 0.55 |
| ▸ | FNTB | P49356 | 1/20 | 0.55 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.54 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.54 |
| ▸ | SIRT3 | Q9NTG7 | 2/20 | 0.54 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.53 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.53 |
| ▸ | TLR2 | O60603 | 2/20 | 0.53 |
| ▸ | MME | P08473 | 1/20 | 0.52 |
| ▸ | ANPEP | P15144 | 1/20 | 0.52 |
| ▸ | CTSL | P07711 | 1/20 | 0.51 |
| ▸ | CTSS | P25774 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11705092 | 0.92 | FNTA (0.62) | CA1FNTAFNTBMMEANPEP | |
| SCHEMBL11705090 | 0.92 | FNTA (0.62) | CA1FNTAFNTBMMEANPEP | |
| SCHEMBL24188458 | 0.88 | ECE1 (0.62) | ECE1CPB1CPB2ACESIRT2 | |
| SCHEMBL1157282 | 0.87 | FNTA (0.64) | CA1FNTAFNTBSIRT2SIRT1 | |
| SCHEMBL287475 | 0.87 | ITGB3 (0.66) | ECE1CPB1CPB2ACESIRT2 | |
| SCHEMBL287474 | 0.87 | ITGB3 (0.66) | ECE1CPB1CPB2ACESIRT2 | |
| SCHEMBL15968143 | 0.87 | ITGB3 (0.66) | ECE1CPB1CPB2ACESIRT2 | |
| SCHEMBL151601 | 0.87 | FNTA (0.64) | CA1FNTAFNTBSIRT2SIRT1 | |
| SCHEMBL4169134 | 0.87 | FNTA (0.64) | CA1FNTAFNTBSIRT2SIRT1 | |
| SCHEMBL6476819 | 0.87 | ITGB3 (0.66) | ECE1CPB1CPB2ACESIRT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1109928-A4 | ENZYMATIC OXIDATIVE DEAMINATION PROCESS | BRISTOL MYERS SQUIBB CO (US) | 2004-10-13 | — | — | EP | disclosed |
| US-6649387-B2 | From dipeptides | BRISTOL-MYERS SQUIBB COMPANY | 2003-11-18 | — | — | US | disclosed |
| US-6515170-B1 | The present invention concerns an enzymatic oxidative deamination process to prepare an intermediate useful to prepare compounds having endopeptidase and angiotensin converting enzyme inhibition activity. | BRISTOL-MYERS SQUIBB CO. | 2003-02-04 | — | — | US | disclosed |
| US-20020025566-A1 | Enzymatic oxidative deamination process | PATEL RAMESH N (US) | 2002-02-28 | — | — | US | disclosed |
| US-6261810-B1 | PREPARING SPECIFIC AMINO LACTAM COMPOUND BY CONTACTING DIPEPTIDE MONOMER WITH AMINOTRANSFERASE IN PRESENCE OF ALPHA-KETOGLUTARATE; FORMING CHEMICAL INTERMEDIATES OF INHIBITORS OF ENDOPEPTIDASE AND ANGIOTENSIN CONVERTING ENZYME | BRISTOL-MYERS SQUIBB COMPANY | 2001-07-17 | — | — | US | disclosed |
| EP-1109928-A1 | ENZYMATIC OXIDATIVE DEAMINATION PROCESS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-06-27 | — | — | EP | disclosed |
| WO-2000014265-A1 | ENZYMATIC OXIDATIVE DEAMINATION PROCESS | BRISTOL-MYERS SQUIBB CO. (US) | 2000-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020025566-A1 | Enzymatic oxidative deamination process | DNPEP, PEPD, ACE | ECE1 25/4885CPB1 36/4885CPB2 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.